CRDF · Insider Trading
Cardiff Oncology, Inc. Common Stock
Every open-market purchase and sale reported by CRDF officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-16 | Mani Mohindru | Chief Executive Officer | Buy | +34,364 | +$50.00K |
| 2026-07-16 | Gary W Pace | Director | Buy | +687,285 | +$1000.00K |
| 2026-06-22 | Mani Mohindru | Chief Executive Officer | Buy | +24,703 | +$29.89K |
| 2026-06-22 | Gary W Pace | Director | Buy | +30,000 | +$36.60K |
| 2026-06-15 | Renee P Tannenbaum | Director | A | +40,565 deriv. | — |
| 2026-06-15 | Gary W Pace | Director | A | +40,565 deriv. | — |
| 2026-06-15 | James O Armitage | Director | A | +40,565 deriv. | — |
| 2026-06-15 | Rodney S Markin | Director | A | +40,565 deriv. | — |
| 2026-06-15 | Lale White | Director | A | +40,565 deriv. | — |
| 2026-04-28 | Ajay Aggarwal | Chief Operating Officer | A | +400,000 deriv. | — |
| 2026-04-16 | Joshua B Muntner | Chief Financial Officer | A | — | — |
| 2026-04-16 | Tod Smeal | Chief Scientific Officer | A | +300,000 deriv. | — |
| 2026-04-16 | Joshua B Muntner | Chief Financial Officer | A | +486,650 deriv. | — |
| 2026-04-02 | Mani Mohindru | Chief Executive Officer | A | +600,000 deriv. | — |
| 2026-02-18 | Mani Mohindru | Interim CEO | A | +200,000 deriv. | — |
| 2026-02-18 | Brigitte Ute Lindsay | Chief Accounting Officer | A | +200,000 deriv. | — |
| 2025-07-31 | Gary W Pace | Director | Buy | +290,000 | +$710.50K |
| 2025-06-30 | Mani Mohindru | Director | A | +40,565 deriv. | — |
| 2025-06-30 | Renee P Tannenbaum | Director | A | +40,565 deriv. | — |
| 2025-06-30 | Rodney S Markin | Director | A | +40,565 deriv. | — |
| 2025-06-27 | James O Armitage | Director | A | +40,565 deriv. | — |
| 2025-06-27 | Gary W Pace | Director | A | +40,565 deriv. | — |
| 2025-06-27 | Lale White | Director | A | +40,565 deriv. | — |
| 2025-03-13 | James E. Levine | Chief Financial Officer | A | +332,621 deriv. | — |
| 2025-03-13 | Tod Smeal | Chief Scientific Officer | A | +332,621 deriv. | — |
| 2025-03-13 | Fairooz Kabbinavar | Chief Medical Officer | A | +150,000 deriv. | — |
| 2025-03-13 | Mark Erlander | Chief Executive Officer | A | +758,400 deriv. | — |
| 2024-12-18 | James E. Levine | Chief Financial Officer | Buy | +7,716 | +$36.73K |
| 2024-12-16 | Renee P Tannenbaum | Director | Buy | +10,000 | +$34.22K |
| 2024-12-12 | Gary W Pace | Director | Buy | +361,615 | +$940.20K |
| 2024-07-01 | Lale White | Director | A | +29,700 deriv. | — |
| 2024-07-01 | Gary W Pace | Director | A | +29,700 deriv. | — |
| 2024-07-01 | James O Armitage | Director | A | +29,700 deriv. | — |
| 2024-07-01 | Rodney S Markin | Director | A | +29,700 deriv. | — |
| 2024-07-01 | Renee P Tannenbaum | Director | A | +29,700 deriv. | — |
| 2024-07-01 | Mani Mohindru | Director | A | +29,700 deriv. | — |
| 2024-03-07 | Tod Smeal | Chief Scientific Officer | A | +205,008 deriv. | — |
| 2024-03-07 | Mark Erlander | Chief Executive Officer | A | +510,000 deriv. | — |
| 2024-03-07 | Fairooz Kabbinavar | Chief Medical Officer | A | +205,008 deriv. | — |
| 2024-03-07 | James E. Levine | Chief Financial Officer | A | +205,008 deriv. | — |
| 2023-12-19 | Gary W Pace | Director | Buy | +30,000 | +$41.10K |
| 2023-11-14 | Gary W Pace | Director | Buy | +22,950 | +$22.49K |
| 2023-06-20 | Lale White | Director | A | +27,700 deriv. | — |
| 2023-06-20 | Rodney S Markin | Director | A | +27,700 deriv. | — |
| 2023-06-20 | Mani Mohindru | Director | A | +27,700 deriv. | — |
| 2023-06-20 | James O Armitage | Director | A | +27,700 deriv. | — |
| 2023-06-20 | Renee P Tannenbaum | Director | A | +27,700 deriv. | — |
| 2023-06-20 | Gary W Pace | Director | A | +27,700 deriv. | — |
| 2023-03-16 | Mark Erlander | Chief Executive Officer | A | +482,064 deriv. | — |
| 2023-03-16 | James E. Levine | Chief Financial Officer | A | +197,472 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Gary W Pace | Director | 3,389,337 | $2.73M |
| James E. Levine | Chief Financial Officer | 125,316 | $100.79K |
| Lale White | Director | 113,788 | $91.52K |
| Mani Mohindru | Chief Executive Officer | 59,067 | $47.51K |
| Rodney S Markin | Director | 31,060 | $24.98K |
| James O Armitage | Director | 27,490 | $22.11K |
| Mark Erlander | Chief Executive Officer | 24,481 | $19.69K |
| Renee P Tannenbaum | Director | 20,000 | $16.09K |
| Joshua B Muntner | Chief Financial Officer | 500 | $402 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRDF quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.